39 completed. 39 Phase 2, 3 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 39 | Completed 39 |
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 3 | Completed 3 |
Follow PTSD: new trials by email Literature Review of PTSD trials Research Report on PTSD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intranasal Insulin for Posttraumatic Stress Disorder Intranasal insulin, Placebo - PTSD | Phase 2 | Completed | VA Connecticut Healthcare System | 10 | 2024-10-31 | 2026-07-13 |
| Group MDMA-therapy for Veterans With PTSD MDMA, Group Therapy - PTSD | Phase 1 / Phase 2 | Completed | Portland VA Research Foundation, Inc | 23 | 2023-10-01 | 2025-06-12 |
| Glecaprevir/Pibrentasvir for the Treatment of PTSD Glecaprevir / Pibrentasvir Pill - PTSD | Phase 2 / Phase 3 | Completed | White River Junction Veterans Affairs Medical Center | 10 | 2023-04-01 | 2024-08-29 |
| Psilocybin for the Treatment of Veterans With Post-Traumatic Stress Disorder Psilocybin - PTSD, Stress Disorders, Traumatic | Phase 2 | Completed | Ohio State University | 12 | 2023-01-01 | 2026-10-16 |
| Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment of Veterans With Posttraumatic Stress Disorder (PTSD) (Seven Study) CORT108297, Placebo - PTSD | Phase 2 | Completed | VA Office of Research and Development | 39 | 2022-10-15 | 2026-10-27 |
| Acceptability and Feasibility of Apollo in Veterans With a History of PTSD Apollo Wearable System - PTSD | Phase 2 | Completed | Lisa Brenner | 63 | 2022-02-01 | 2025-11-17 |
| Methylphenidate for Ptsd and Stroke Veterans Methylphenidate, Placebo - PTSD, Stroke | Phase 1 / Phase 2 | Completed | VA Office of Research and Development | 20 | 2022-01-14 | 2025-06-22 |
| PTSD Prevention Using Oral Hydrocortisone Placebo, Hydrocortisone - PTSD, Acute Stress Disorder | Phase 2 | Completed | Rachel Yehuda | 201 | 2022-01-12 | 2026-03-19 |
| Stellate Ganglion Block to Augment Trauma-focused Therapy Among Veterans With PTSD Cognitive Processing Therapy (CPT), Stellate Ganglion Block - PTSD, Trauma and Stressor Related Disorders | Phase 2 | Completed | Ohio State University | 85 | 2022-01-03 | 2025-07-03 |
| Adding Trauma-focused Psychotherapy to Ketamine Treatment for Chronic PTSD Ketamine, Written Exposure Therapy - PTSD | Phase 2 | Completed | Icahn School of Medicine at Mount Sinai | 16 | 2021-06-04 | 2024-10-08 |
| Oxytocin to Enhance Integrated Treatment for AUD and PTSD 40 IU Intranasal Oxytocin, Placebo, Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure - PTSD, Alcohol Use Disorder | Phase 2 | Completed | Medical University of South Carolina | 175 | 2021-03-29 | 2026-07-27 |
| Ketamine-enhanced Prolonged Exposure Therapy in PTSD Ketamine, Midazolam - PTSD | Phase 2 | Completed | VA Office of Research and Development | 73 | 2021-03-09 | 2026-08-11 |
| Oxytocin to Treat PTSD Oxytocin, Placebo - PTSD | Phase 2 | Completed | VA Office of Research and Development | 180 | 2021-01-01 | 2026-03-11 |
| Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study Midomafetamine HCl - PTSD | Phase 2 | Completed | MAPS Europe B.V. | 21 | 2020-06-24 | 2025-01-28 |
| Cannabidiol and Prolonged Exposure Prolonged Exposure, Cannabidiol, placebo - PTSD | Phase 2 | Completed | VA Office of Research and Development | 136 | 2019-10-01 | 2026-10-28 |
| Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD Midomafetamine, Manualized therapy - PTSD | Phase 2 | Completed | Resilient Pharmaceuticals | 38 | 2017-11-16 | 2025-06-05 |
| CAP-Ketamine for Antidepressant Resistant PTSD Ketamine, Placebo/Saline - PTSD, Posttraumatic Stress Disorder | Phase 2 | Completed | VA Office of Research and Development | 163 | 2016-04-18 | 2022-06-02 |
| Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions TNX-102 SL - PTSD | Phase 2 | Completed | Tonix Pharmaceuticals, Inc. | 159 | 2015-04-14 | 2025-02-06 |
| Prolonged Exposure and Oxytocin Oxytocin, Placebos - PTSD | Phase 2 | Completed | Medical University of South Carolina | 17 | 2015-01-01 | 2018-05-25 |
| Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions TNX-102 SL, Placebo - PTSD | Phase 2 | Completed | Tonix Pharmaceuticals, Inc. | 245 | 2014-10-01 | 2024-06-20 |
Showing 20 of 39. Sign in to see all of them.
Stress Disorders, Post-Traumatic (39) · Alcoholism (4) · Behavior, Addictive (2) · Depression (2) · Psychological Well-Being (2) · Trauma and Stressor Related Disorders (2) · Anxiety Disorders (1) · Consciousness Disorders (1) · Emotional Regulation (1) · Hepatitis C (1) · Mental Disorders (1) · Psychological Trauma (1) · Stress Disorders, Traumatic (1) · Stress Disorders, Traumatic, Acute (1) · Stroke (1)
Mental Disorders (38) · Stress Disorders, Traumatic (38) · Trauma and Stressor Related Disorders (37) · Behavior (6) · Chemically-Induced Disorders (5) · Alcohol-Related Disorders (4) · Substance-Related Disorders (4) · Behavioral Symptoms (2) · Compulsive Behavior (2) · Impulsive Behavior (2) · Nervous System Diseases (2) · Personal Satisfaction (2) · Blood-Borne Infections (1) · Brain Diseases (1) · Cardiovascular Diseases (1)
Ketamine (4) · Oxytocin (4) · Sodium Chloride (4) · N-Methyl-3,4-methylenedioxyamphetamine (3) · Cognitive Behavioral Therapy (2) · Cycloserine (2) · Midazolam (2) · Therapeutics (2) · 7-oxodehydroepiandrosterone (1) · Acetylcysteine (1) · Aripiprazole (1) · CORT 108297 (1) · Cannabidiol (1) · Educational Status (1) · Hydrocortisone (1)
VA Office of Research and Development (7) · Medical University of South Carolina (4) · UConn Health (3) · Ohio State University (2) · Tonix Pharmaceuticals, Inc. (2) · Tulane University School of Medicine (2) · Baylor College of Medicine (1) · Collinge and Associates, Inc. (1) · Dennis Charney (1) · Durham VA Medical Center (1) · Humanetics Corporation (1) · Icahn School of Medicine at Mount Sinai (1) · Lisa Brenner (1) · MAPS Europe B.V. (1) · Marinus Pharmaceuticals (1)
United States (34) · Czechia (1) · Germany (1) · Israel (1) · Netherlands (1) · Norway (1) · United Kingdom (1)
Christine E Marx, MD, MA (2) · Denise Bedoya (2) · Julian Ford, Ph.D. (2) · Michael S Scheeringa, MD, MPH (2) · Adriana Feder, MD (1) · Alan K Davis, PhD (1) · Alina Gonzalez-Mayo, MD (1) · Ann Rasmusson, MD (1) · Bradley V Watts, MD, MPH (1) · Brian Martis, MD (1) · Catherine R Ayers, PhD (1) · Chen Lin, MD (1) · Craig J Bryan, PsyD (1) · David M Benedek, MD (1) · Dennis Charney, MD (1)
PMID 24506079, PMID 28569390, PMID 21194898, PMID 24368465, PMID 24740528, PMID 26515712, PMID 27459380, PMID 27678169, PMID 27736051, PMID 28667510, PMID 28682105, PMID 29294429, PMID 31017639, PMID 32521096, PMID 32557843, PMID 32561468, PMID 32608505, PMID 32673006, PMID 33113596, PMID 33979763, PMID 34455213, PMID 34941354, PMID 36405923, PMID 36646315, PMID 37142308, PMID 37384482, PMID 38767196, PMID 40215385, PMID 41947855, PMID 42533157
1RC1AA019019-01 (1), 1RC1MH088969-01 (1), I01CX001917 (1), IK2CX002104 (1), K23AA015707 (1)